THTianyu Han

Tianyu Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tianyu Han has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Yanan Wang

    Jiangxi Provincial Key Laboratory of Respiratory Diseases Jiangxi Institute of Respiratory Diseases Jiangxi Clinical Research Center for Respiratory Diseases Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital Jiangxi Medical College Nanchang University Nanchang Jiangxi Province P.R. China

    12 shared publications
  • Mingxi Gan

    School of Basic Medical Sciences, Nanchang University, Nanchang, P. R. China

    8 shared publications
  • Qifan Hu

    Department of Thoracic Surgery The First Affiliated Hospital of Nanchang University Nanchang Jiangxi 330006 China

    8 shared publications
  • Jian-Bin Wang

    Department of Thoracic Surgery The First Affiliated Hospital of Nanchang University Nanchang Jiangxi 330006 China

    7 shared publications
  • Keru Wang

    Jiangxi Institute of Respiratory Disease, the Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330052, China

    6 shared publications
  • Wenze Xun

    Department of Thoracic Surgery The First Affiliated Hospital of Nanchang University Nanchang Jiangxi 330006 China

    6 shared publications

Latest Publications

  • Open Access

    4‐Hydroxytamoxifen induces a noncanonical ferroptosis in lung adenocarcinoma by targeting AKR1B10

    by Hui Yang, Yanan Wang, Jiangbo Jin, Hanyan Xu, Yinshui Miao, Xiaojing Wu, Shengsong Chen, Tianyu Han, Qingyuan Zhan

    Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, and current therapies are limited by drug resistance and toxicity. Ferroptosis offers an attractive strategy for cancer therapy, but classical ferroptosis is iron‑dependent. Repurposing approved drugs offers a rapid strategy to identify novel anti‑LUAD agents, yet the mechanism by which 4‑Hydroxytamoxifen (4‑OHT) exerts estrogen receptor–independent anti‑tumour effects remains unclear. Methods: We performed a drug repurposing screen of 950 endogenous metabolites in LUAD cells. Anti‑tumour activity was validated in vitro and in vivo using LUAD cell lines and mouse models. Target identification and mechanistic studies employed LiP‑MS, pull‐down SPR, CETSA, metabolomics, and enzyme activity assays. Clinical relevance was assessed via tissue microarrays and TCGA analysis. Drug synergy was quantified using the Chou–Talalay method. Results: 4‑OHT inhibited LUAD cell proliferation with IC 50 values of 3.86 ± 0.26 µM to 13.58 ± 0.55 µM independent of estrogen receptor. It triggered noncanonical ferroptosis characterised by GSH depletion (reduced by about 60%), GPX4 downregulation, lipid peroxidation (about 2.5‐fold increase), and iron independence. Mechanistically, 4‑OHT directly bound AKR1B10 (K D (M) was 7.98e‐06) and inhibited its enzymatic activity, leading to ACC1 degradation, lipid deficiency, and accumulation of toxic lipid‑derived carbonyls. AKR1B10 knockout abolished 4‑OHT‑induced cell death, while rescue restored sensitivity. Nanatinostat similarly targeted AKR1B10 and induced the same cell death modality. AKR1B10 upregulation in LUAD tissues correlated with reduced overall survival rates. Conclusion: This study demonstrates that 4‑OHT directly inhibits AKR1B10 enzymatic activity to induce a noncanonical ferroptosis in LUAD. AKR1B10 overexpression correlates with poor prognosis and chemoresistance in LUAD patients. Nonetheless, AKR1B10 inhibition warrants further investigation as a therapeutic strategy. Highlights: 4‑OHT directly inhibits AKR1B10 enzymatic activity to induce noncanonical ferroptosis in LUAD. AKR1B10 sustains LUAD survival by stabilising ACC1 and detoxifying reactive carbonyl species (RCSs). Nanatinostat similarly targets AKR1B10 and elicits the same cell death modality. AKR1B10 overexpression correlates with poor prognosis and chemoresistance in LUAD.

  • Baohuoside I induces GSDME-dependent pyroptosis and synergistically inhibits lung adenocarcinoma with cisplatin

    by Ying Yang, Luchanghao Zheng, Tao Zhao, Yi Zhang, Ruiguang Luo, Shiyan Xie, Guilan Wen, Zhujun Cheng, Tianyu Han


  • Open Access

    The mutual regulation of SOX12 and RNF168 modulates cisplatin resistance in esophageal squamous cell carcinoma cells by regulating DNA damage repair

    by Ning Wang, Lun Yang, Yunhe Huang, Yanan Wang, Mingshan Liu, Jie Yang, Zhikai Zeng, Guobin Xie, Longhua Sun, Tianyu Han, et al.

    Resistance to chemotherapy drugs is one of the significant factors for limited treatment options and poor prognosis in esophageal cancer. A study has found

  • Open Access

    Serine metabolism reprogramming in cancer: a multi-tiered regulatory framework

    by Yi Yuan, Keru Wang, Yuxin Jin, Tianyu Han

    As a critical component of amino acid metabolic reprogramming, serine metabolism has been demonstrated to be enhanced in a variety of cancer types, thereby supporting tumor progression. This enhancement is primarily driven by increased expression levels and augmented enzymatic activity of serine metabolic enzymes (phosphoglycerate dehydrogenase, phosphoserine aminotransferase 1, phosphoserine phosphatase and serine hydroxymethyltransferase). However, there is still lack of comprehensive summary on the regulation of serine metabolism in cancer. In this review, we provide a systematic overview of the currently discovered and proven regulatory mechanisms of serine metabolic enzymes in cancer, focusing on three levels: transcriptional, post-transcriptional, and post-translational regulation. Specifically, transcriptional regulation encompasses three major mechanisms: (1) transcription factor-mediated gene expression control, (2) histone modifications, and (3) DNA methylation. At the post-transcriptional level, regulation is primarily achieved through (1) non-coding RNAs, (2) RNA-binding proteins, and (3) RNA modifications. Post-translational regulation is predominantly mediated through diverse protein post-translational modifications. The transcriptional and post-transcriptional mechanisms primarily modulate the expression levels of serine metabolic enzymes, while post-translational modifications exert more diverse effects by altering the activity, protein stability or cellular localization of these enzymes. These regulations collectively modulate serine metabolism to influence tumor progression, offering promising targets for tumor-specific therapeutic interventions.

  • Open Access

    Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma

    by Jizhuo Li, Wenze Xun, Xijie Wang, Ruiguang Luo, Qifan Hu, Zhaocai Zhou, Jian Yuan, Yanan Wang, Xiaorui Wan, Tao Zhao, et al.

    Lactylation is a novel post‐translational modification closely related to the glycolytic process, but the regulatory mechanisms between lactylation and glycolysis are far from being elucidated. Lactate dehydrogenase A (LDHA) catalyzes the formation of lactate, which provides the modifying group for protein lactylation. However, whether lactylation occurs on LDHA itself remains unknown. Here, it is found that lactylation promotes the enzymatic activity of LDHA in lung adenocarcinoma (LUAD), which in turn enhances the overall level of cellular lactylation through a positive feedback loop. Screening identified Lys81 and Lys318 as key LDHA lactylation sites, with alanyl‐tRNA synthetase 1 (AARS1) serving as the mediating lactyltransferase. Mass spectrometry reveals that numerous proteins involved in DNA nonhomologous end junction (NHEJ), including FEN1, XRCC5, and XRCC6 might be regulated by lactylation. Delactylation of these proteins significantly hinders the formation of FEN1‐RAD1‐RAD9A‐HUS1 complex, thereby leading to dysfunction of NHEJ and increasing the sensitivity of cancer cells to cisplatin. In summary, this work identifies LDHA lactylation as a critical mechanism for accelerating the progression of LUAD and reveals how this lactylation influenced cisplatin sensitivity of LUAD cells, which deepen the understanding of lactylation‐mediated tumor progression and provide a potential new anticancer strategy.


  • Open Access

    NSP6 regulates calcium overload-induced autophagic cell death and is regulated by KLHL22-mediated ubiquitination

    by Xingyu Tao, Yanan Wang, Jiangbo Jin, Huilin Yan, Hui Yang, Xiaorui Wan, Ping Li, Yanghua Xiao, Qi Yu, Lingjiao Liu, et al.


  • Open Access

    Author Correction: EGFR-ERK induced activation of GRHL1 promotes cell cycle progression by up-regulating cell cycle related genes in lung cancer

    by Yiming He, Mingxi Gan, Yanan Wang, Tong Huang, Jianbin Wang, Tianyu Han, Bentong Yu

  • Open Access

    Interplay between acetylation and ubiquitination controls PSAT1 protein stability in lung adenocarcinoma

    by Yuhan Liu, Wenze Xun, Tao Zhao, Menglin Huang, Longhua Sun, Guilan Wen, Xiuhua Kang, Jianbin Wang, Tianyu Han

    Serine is essential to maintain maximal growth and proliferation of cancer cells by providing adequate intermediate metabolites and energy. Phosphoserine aminotransferase 1 (PSAT1) is a key enzyme in de novo serine synthesis. However, little is known about the mechanisms underlying PSAT1 degradation. We found that acetylation was the switch that regulated the degradation of PSAT1 in lung adenocarcinoma (LUAD). Deacetylation of PSAT1 on Lys51 by histone deacetylase 7 (HDAC7) enhanced the interaction between PSAT1 and the deubiquitinase ubiquitin-specific processing protease 14 (USP14), leading to the deubiquitination and stabilization of PSAT1; while acetylation of PSAT1 promoted its interaction with the E3 ligase ubiquitination factor E4B (UBE4B), leading to proteasomal degradation. Acetylation of PSAT1 on Lys51 regulated serine metabolism and tumor proliferation in LUAD. Thus, acetylation and ubiquitination cooperatively regulated the protein homeostasis of PSAT1. In conclusion, our study reveals a key regulatory mechanism for maintaining PSAT1 protein homeostasis in LUAD.


  • Open Access

    Deacetylation of GLUD1 maintains the survival of lung adenocarcinoma cells under glucose starvation by inhibiting autophagic cell death

    by Qifan Hu, Longhua Sun, Zhujun Cheng, Lei Wang, Xiaorui Wan, Jing Xu, Junyao Cheng, Zuorui Wang, Yi Yuan, Keru Wang, et al.


  • Open Access

    Phosphorylated SHMT2 Regulates Oncogenesis Through m6A Modification in Lung Adenocarcinoma

    by Tianyu Han, Yanan Wang, Minzhang Cheng, Qifan Hu, Xiaorui Wan, Menglin Huang, Yuhan Liu, Wenze Xun, Jin Xu, Lei Wang, et al.

    Targeting cancer‐specific metabolic processes is a promising therapeutic strategy. Here, this work uses a compound library that directly inhibits metabolic enzymes to screen the potential metabolic targets in lung adenocarcinoma (LUAD). SHIN1, the specific inhibitor of serine hydroxymethyltransferase 1/2 (SHMT1/2), has a highly specific inhibitory effect on LUAD cells, and this effect depends mainly on the overexpression of SHMT2. This work clarifies that mitogen‐activated protein kinase 1 (MAPK1)‐mediated phosphorylation at Ser90 is the key mechanism underlying SHMT2 upregulation in LUAD and that this phosphorylation stabilizes SHMT2 by reducing STIP1 homology and U‐box containing protein 1 (STUB1)‐mediated ubiquitination and degradation. SHMT2‐Ser90 dephosphorylation decreases S‐adenosylmethionine levels in LUAD cells, resulting in reduced N6‐methyladenosine (m6A) levels in global RNAs without affecting total protein or DNA methylation. Methylated RNA immunoprecipitation sequencing (MeRIP‐Seq) and RNA sequencing (RNA‐Seq) analyses further demonstrate that SHMT2‐Ser90 dephosphorylation accelerates the RNA degradation of oncogenic genes by reducing m6A modification, leading to the inhibition of tumorigenesis. Overall, this study elucidates a new regulatory mechanism of SHMT2 during oncogenesis and provides a theoretical basis for targeting SHMT2 as a therapeutic target in LUAD.